 NEW YORK and LONDON, Feb. 02, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc Nasdaq: TLSA LSE: TILS Tiziana or the Company, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, reports positive data from the exploratory clinical study in Brazil investigating nasally administered Foralumab, its proprietary anti-CD3 human monoclonal antibody, either alone or in combination with orally administered dexamethasone Dexa in COVID-19 patients. The clinical study was completed in collaboration with scientific teams at the Harvard Medical School Boston, USA, and INTRIALS, a full-service Latin American CRO based in São Paulo, Brazil. 